Amryt Pharma PLC (LON:AMYT) (NASDAQ:AMYT) CEO Joey Wiley tells Proactive it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year.
Wiley says the biopharma company, which acquires, develops and commercializes novel treatments for rare diseases, generated revenue growth of 18.5% to US$182.6M for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder.